Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B
| dc.contributor.author | Rugivarodom M. | |
| dc.contributor.author | Pongpaibul A. | |
| dc.contributor.author | Chainuvati S. | |
| dc.contributor.author | Nimanong S. | |
| dc.contributor.author | Chotiyaputta W. | |
| dc.contributor.author | Tanwandee T. | |
| dc.contributor.author | Charatcharoenwitthaya P. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2023-05-19T08:29:28Z | |
| dc.date.available | 2023-05-19T08:29:28Z | |
| dc.date.issued | 2023-01-01 | |
| dc.description.abstract | Background and Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is prevalent in patients with chronic hepatitis B (CHB). The effect of the histologic MAFLD phenotype on long-term CHB outcomes is unknown. We performed a longitudinal study to determine the prognostic relevance of biopsy-proven hepatic steatosis and steatohepatitis for CHB patients. Methods: Clinical and laboratory data were obtained from CHB patients who underwent liver biopsy during 2002–2008 and were treated with antiviral drugs. A hepatopathologist reviewed the biopsy specimens. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (aHR) of outcomes, including all-cause mortality, liver transplantation, and liver-related events. Results: In accordance with Brunt’s classification, 408 patients had steatohepatitis (n=34), “steatosis but not steatohepatitis” (n=118), or “non-steatosis” (n=256). All steatohepatitis patients had features of metabolic dysfunction. Over a mean follow-up of 13.8±3.1 years, 18 patients died or underwent liver transplantation. In multivariate-adjusted analysis, steatohepatitis (aHR, 6.37; 95% confidence interval [CI]: 1.59– 25.5) compared with non-steatosis and advanced fibrosis (aHR, 11.3; 95% CI: 1.32–96.3) compared with no fibrosis were associated with overall mortality/liver transplantation. Thirty-five patients developed 43 liver-related events, among which 32 were hepatocellular carcinoma. These events were associated with steatohepatitis (aHR, 5.55; 95% CI: 2.01– 15.3) compared with non-steatosis and advanced fibrosis (aHR, 6.23; 95% CI: 1.75–22.2) compared with no fibrosis. The steatosis but not steatohepatitis group had a nonsignificantly higher risk of overall mortality and liver-related events. Conclusions: Metabolic dysfunction-associated steatohepatitis increased the risk of long-term mortality/transplantation and liver-related events in CHB patients. | |
| dc.identifier.citation | Journal of Clinical and Translational Hepatology Vol.11 No.1 (2023) , 76-87 | |
| dc.identifier.doi | 10.14218/JCTH.2022.00055 | |
| dc.identifier.eissn | 23108819 | |
| dc.identifier.issn | 22250719 | |
| dc.identifier.scopus | 2-s2.0-85141540006 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/82639 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85141540006&origin=inward | |
| oaire.citation.endPage | 87 | |
| oaire.citation.issue | 1 | |
| oaire.citation.startPage | 76 | |
| oaire.citation.title | Journal of Clinical and Translational Hepatology | |
| oaire.citation.volume | 11 | |
| oairecerif.author.affiliation | Siriraj Hospital |
